Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4639207 | 0.85 | BRD4 (0.42) | DPP4DPP8RIPK1ALDH1A1 | |
| SCHEMBL19638457 | 0.85 | CAMK2A (0.47) | DPP4DPP8AKR1C3SRD5A1RIPK1 | |
| SCHEMBL3664186 | 0.81 | DPP4 (0.42) | DPP4DPP8AKR1C3AKR1C1 | |
| SCHEMBL3657288 | 0.79 | HDAC6 (0.40) | DPP4DPP8ALDH1A1 | |
| SCHEMBL4032578 | 0.77 | ESR1 (0.51) | — | |
| SCHEMBL3662939 | 0.77 | MTNR1B (0.41) | AKR1C3SRD5A1 | |
| SCHEMBL31546529 | 0.76 | CAMK2A (0.43) | DPP4DPP8AKR1C3SRD5A1CAMK2A | |
| SCHEMBL3664252 | 0.76 | NR1H2 (0.45) | DPP4DPP8 | |
| SCHEMBL2123936 | 0.76 | CAMK2A (0.43) | DPP4DPP8AKR1C3SRD5A1CAMK2A | |
| SCHEMBL4638198 | 0.76 | DPP4 (0.36) | DPP4DPP8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222669-B1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-8222245-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (S1P) | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20100273771-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2222669-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | Glaxo Group Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-20100174065-A1 | COMPOUNDS | GLAXO GROUP LIMITED (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2009080725-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174065-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | DPP4 100/4885DPP8 201/4885AKR1C3 815/4885 |
| US-20100273771-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | S1PR3, S1PR1, S1PR2 | DPP4 575/4885DPP8 830/4885AKR1C3 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.